Symptomatic relief from treatment‐induced psychosis in Parkinson's disease: An open‐label pilot study with remoxipride

Modification of Parkinsonism — Chronic Treatment with L-Dopa

1969 • 1,253 citations

Biochemical pathophysiology of Parkinson's disease.

1987 • 844 citations

Irreversible motor impairment in young addicts ? ephedrone, manganism or both?

2007 • 655 citations

Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain

1984 • 213 citations

Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.

1993 • 207 citations

OCCURRENCE AND DISTRIBUTION OF AROMATIC <scp>l</scp>‐AMINO ACID (<scp>l</scp>‐DOPA) DECARBOXYLASE IN THE HUMAN BRAIN

1972 • 143 citations

Handbook of Parkinson's Disease

1988 • 131 citations

Drug holiday and management of Parkinson disease

1980 • 98 citations

Psychiatric side effects during the treatment of Parkinson’s disease

1988 • 73 citations

A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial

1990 • 44 citations

An open multicentre study of the treatment of florid schizophrenia with remoxipride

1985 • 37 citations

Visual hallucinations in the elderly associated with the use of levodopa

1989 • 30 citations

Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients

1990 • 22 citations

Remoxipride in schizophrenia

1986 • 19 citations

Behavioral Alterations and the Therapy of Parkinsonism

1982 • 19 citations

Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy

1986 • 11 citations

Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.

1990 • 7 citations

National Conference on Parkinson's Disease

1991 • 4 citations